Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.

  title={Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.},
  author={Shuichi Kaneko and Junji Furuse and Masatoshi Kudo and Kenji Ikeda and Masao Honda and Yasunari Nakamoto and Morikazu Onchi and Goshi Shiota and Osamu Yokosuka and Isao Sakaida and Tetsuo Takehara and Yoshiyuki Ueno and Kazumasa Hiroishi and Shuhei Nishiguchi and Hisataka Moriwaki and Kazuhide Yamamoto and Michio Sata and Shuntaro Obi and Shiro Miyayama and Yukinori Imai},
  journal={Hepatology research : the official journal of the Japan Society of Hepatology},
  volume={42 6},
The "Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma" was prepared by the Study Group on New Liver Cancer Therapies established by the "Research Project on Emergency Measures to Overcome Hepatitis" under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 25 extracted citations


Publications referenced by this paper.
Showing 1-10 of 29 references

Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib

D Spira
Acad Radiol. • 2011

Chapter 3 Treatment strategy for HCC cases refractory for TACE (Japanese). Hepatocelluar carcinoma practice manual 2nd edition, Igaku-syoin

M. Kudo

PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinom

K Ueshima, M Kudo
Kanzo. • 2010

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

CH Hsu
J Hepatol. • 2010

Similar Papers

Loading similar papers…